ACHFF Stock Chart & Stats
$0.72
<$0.01(1.48%)
At close: 4:00 PM EDT
$0.72
<$0.01(1.48%)
Day’s Range― - ―
52-Week Range$0.29 - $1.21
Previous CloseN/A
Volume6.30K
Average Volume (3M)24.18K
Market Cap
$41.73M
Enterprise Value$56.39
Total Cash (Recent Filing)$2.91K
Total Debt (Recent Filing)$2.73M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Feb 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding67,933,290
10 Day Avg. Volume22,578
30 Day Avg. Volume24,177
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)-21.63
Price to Sales (P/S)0.00
P/FCF Ratio-53.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.12
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Therapeutic PipelineA focused pipeline around acute inflammatory and ischemic organ injury gives Arch Biopartners a clear strategic direction. Concentrating resources on LSALT and related mechanisms may support efficient development decisions and preserve the potential for a differentiated clinical niche.
Improving Cash UsageCash consumption has moderated meaningfully compared with earlier periods, indicating some improvement in operating discipline or resource use. Although the company remains cash-flow negative, a lower burn rate could extend financial flexibility and support continued development activity.
Narrower Annual LossesThe reduction in annual net losses shows that reported expenses have become more manageable than in the prior year. If maintained alongside clinical progress, this improvement could reduce funding pressure and improve the company’s ability to allocate capital toward its lead program.
Bears Say
No Current Revenue And Persistent LossesThe absence of TTM revenue and a multi-year pattern of losses demonstrate that Arch Biopartners has not yet commercialized a self-sustaining business. Continued dependence on development success and external funding leaves earnings power uncertain over the next several quarters.
Stressed CapitalizationNegative equity combined with meaningful debt and a very small asset base leaves little balance-sheet cushion. This capitalization can constrain strategic flexibility, increase the importance of future financing, and make it harder to absorb delays or setbacks in development.
No Demonstrated Positive Unit EconomicsNegative gross profit during prior revenue years indicates that the company has not established sustainable unit economics, while ongoing negative free cash flow confirms that operations are not self-funding. This limits confidence that future commercialization would quickly translate into durable profitability.
Arch Biopartners News
ACHFF FAQ
What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was $0.29 and its highest was $1.21 in the past 12 months.
What is Arch Biopartners’s market cap?
Arch Biopartners’s market cap is $41.73M.
When is Arch Biopartners’s upcoming earnings report date?
Arch Biopartners’s upcoming earnings report date is Feb 02, 2027 which is in 135 days.
How were Arch Biopartners’s earnings last quarter?
Arch Biopartners released its earnings results on Aug 31, 2026. The company reported -$0.005 earnings per share for the quarter.
Is Arch Biopartners overvalued?
According to Wall Street analysts Arch Biopartners’s price is currently Overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 67,933,290 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Arch Biopartners reported an EPS of -$0.005 in its last earnings report. Following the earnings report the stock price went down -1.37%.
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in ACHFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arch Biopartners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-47.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-78.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arch Biopartners
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Technical Analysis
Satellos Bioscience
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―